Wen Wei1,2,3, Lingyu Zhang4, Yunhan Zhang5, Ronghui Tang6, Miao Zhao6, Zhidong Huang1, Jin Liu1, Danyuan Xu1, Yibo He1, Bo Wang1, Haozhang Huang3, Qiang Li1, Mengfei Lin4, Yong Liu1,3,7, Kaihong Chen8, Shiqun Chen9. 1. Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. 2. Department of Endocrinology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, China. 3. The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China. 4. Department of Cardiology, Maoming People's Hospital, Maoming, 525000, China. 5. Kunming Medical University, Kunming, 650500, China. 6. Department of Ultrasound Imaging, Yunnan Fuwai Cardiovascular Hospital, Kunming, 650500, China. 7. Guangdong Provincial People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510100, China. 8. Department of Cardiology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, China. chenkaihong1964@163.com. 9. Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. shiqunchen@126.com.
Abstract
BACKGROUND: Predictive value of creatine kinase MB (CK-MB) for contrast-induced acute kidney injury (CI-AKI) among myocardial infarction (MI) patients has rarely been reported. We aim to evaluate the predictive value of CK-MB for CI-AKI among MI patients. METHODS: Totally, 1131 MI patients were included from the REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study. The peak CK-MB before coronary angiography (CAG) was chosen. The study population was divided into two groups by log-transformed CK-MB cut-off point. The association between CK-MB and CI-AKI was tested by multivariable logistic regression. CK-MB was integrated with Age, creatinine and ejection fraction (ACEF) score and Mehran risk score (MRS) to evaluate the additive value of CK-MB. The integrated models were validated internally by the bootstrap method and externally by the PREdictive Value of COntrast voluMe to creatinine Clearance Ratio (PRECOMIN) study data set. RESULTS: Overall, 62(5.48%) patients developed CI-AKI, patients with CK-MB point > 4.7 displayed a higher incidence of CI-AKI than those without (11.9% vs. 4.0%, p < 0.001). CK-MB point > 4.7 was independently associated with CI-AKI (adjusted OR: 3.40, 95% CI: 1.93-5.98, p < 0.001). The additions of CK-MB to ACEF score, Mehran score A and Mehran score B resulted in increases in C-statistics, which ranged from 0.680 to 0.733 (p = 0.046), 0.694 to 0.727 (p = 0.091), 0.704 to 0.734 (p = 0.102), respectively. Internal validation also showed increases in C-statistics, and external validation performed well in discrimination and calibration. CONCLUSIONS: Preprocedural peak CK-MB was a predictor of CI-AKI among MI patients.
BACKGROUND: Predictive value of creatine kinase MB (CK-MB) for contrast-induced acute kidney injury (CI-AKI) among myocardial infarction (MI) patients has rarely been reported. We aim to evaluate the predictive value of CK-MB for CI-AKI among MI patients. METHODS: Totally, 1131 MI patients were included from the REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study. The peak CK-MB before coronary angiography (CAG) was chosen. The study population was divided into two groups by log-transformed CK-MB cut-off point. The association between CK-MB and CI-AKI was tested by multivariable logistic regression. CK-MB was integrated with Age, creatinine and ejection fraction (ACEF) score and Mehran risk score (MRS) to evaluate the additive value of CK-MB. The integrated models were validated internally by the bootstrap method and externally by the PREdictive Value of COntrast voluMe to creatinine Clearance Ratio (PRECOMIN) study data set. RESULTS: Overall, 62(5.48%) patients developed CI-AKI, patients with CK-MB point > 4.7 displayed a higher incidence of CI-AKI than those without (11.9% vs. 4.0%, p < 0.001). CK-MB point > 4.7 was independently associated with CI-AKI (adjusted OR: 3.40, 95% CI: 1.93-5.98, p < 0.001). The additions of CK-MB to ACEF score, Mehran score A and Mehran score B resulted in increases in C-statistics, which ranged from 0.680 to 0.733 (p = 0.046), 0.694 to 0.727 (p = 0.091), 0.704 to 0.734 (p = 0.102), respectively. Internal validation also showed increases in C-statistics, and external validation performed well in discrimination and calibration. CONCLUSIONS: Preprocedural peak CK-MB was a predictor of CI-AKI among MI patients.
Authors: Giuseppe Andò; Gaetano Morabito; Cesare de Gregorio; Olimpia Trio; Francesco Saporito; Giuseppe Oreto Journal: Int J Cardiol Date: 2013-05-24 Impact factor: 4.164
Authors: Emily M Bucholz; Richard P Whitlock; Michael Zappitelli; Prasad Devarajan; John Eikelboom; Amit X Garg; Heather Thiessen Philbrook; Philip J Devereaux; Catherine D Krawczeski; Peter Kavsak; Colleen Shortt; Chirag R Parikh Journal: Pediatrics Date: 2015-03-09 Impact factor: 7.124
Authors: Katarzyna Zbierska-Rubinkiewicz; Oksana Trębacz; Marek Tomala; Mateusz Rubinkiewicz; Iwona Chrzan; Andrzej Gackowski Journal: Folia Med Cracov Date: 2017
Authors: Steven D Weisbord; Paul M Palevsky; James S Kaufman; Hongsheng Wu; Maria Androsenko; Ryan E Ferguson; Chirag R Parikh; Deepak L Bhatt; Martin Gallagher Journal: J Am Coll Cardiol Date: 2020-03-24 Impact factor: 24.094